Christoph Bock

Christoph Bock is a Principal Investigator at CeMM and Professor of [Bio]Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine. Christoph Bock is also scientific coordinator of the Biomedical Sequencing Facility at CeMM, member of the Human Cell Atlas Organizing Committee, fellow of the European Lab for Learning and Intelligent Systems, and elected board member of the Young Academy in the Austrian Academy of Sciences. He has received important research awards, including an ERC Starting Grant (2016-2021), ERC Consolidator Grant (2021-2026), the Otto Hahn Medal of the Max Planck Society (2009), the Overton Prize of the International Society for Computational Biology (2017), and the Erwin Schrödinger Prize of the Austrian Academy of Sciences (2022). He has been listed among the world’s “Highly Cited Researchers” (ISI) since 2019. He co-founded two startup companies in Vienna: Myllia Biotechnology (providing CROP-seq technology) and Neurolentech.

Relevant Publications

• Bock C, Datlinger P, Chardon F, Coelho MA, Dong MB, Lawson KA, Lu T, Maroc L, Norman TM, Song B, Stanley G, Chen S, Garnett M, Li W, Moffat J, Qi LS, Shapiro RS, Shendure J, Weissman JS, Zhuang X (2022). High-content CRISPR screening. Nature Reviews Methods Primers 2, 8.
• Bock C, Boutros M, Camp JG, Clarke L, Clevers H, Knoblich JA, Liberali P, Regev A, Rios AC, Stegle O, Stunnenberg HG, Teichmann SA, Treutlein B, Vries RGJ, the Human Cell Atlas ‘Biological Network’ Organoids (2020). The Organoid Cell Atlas. Nature Biotechnology 39, 13-17.
• Datlinger P, Rendeiro AF#, Boenke T, Senekowitsch M, Krausgruber T, Barreca D, Bock C (2021). Ultra-high-throughput single-cell RNA sequencing and perturbation screening with combinatorial fluidic indexing. Nature Methods 18, 635-642.
• Datlinger P, Schmidl C, Rendeiro A, Krausgruber T, Traxler P, Klughammer J, Schuster L, Kuchler A, Alpar D, Bock C (2017). Pooled CRISPR screening with single-cell transcriptome readout. Nature Methods, 14, 297-301.
• Fortelny N, Bock C (2020). Knowledge-primed neural networks enable biologically interpretable deep learning on single-cell sequencing data. Genome Biology 21, 190.
• Klughammer J, Kiesel B#, [50 middle authors], Woehrer A#, Bock C (2018). The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. Nature Medicine 24, 1611-1624.
• Krausgruber T, Fortelny N#, Fife-Gernedl V, Senekowitsch M, Schuster L, Nemc A, Schmidl C, Rendeiro AF, Lercher A, Bergthaler A, Bock C (2020). Structural cells are key regulators of organ-specific immune response. Nature 583, 296-302.
• Krausgruber T, Redl A#, Barreca D#, Doberer K, Romanovskaia D, Dobnikar L, Guarini M, Unterluggauer L, Kleissl L, Atzmüller D, Mayerhofer C, Kopf A, Saluzzo S, Lim CX, Rexie P, Weichhart T, Bock C*, Stary G* (2023). Single-cell and spatial transcriptomics identify aberrant developmental programs driving granuloma for-mation. Immunity 56, 289-306 e287.
• Rendeiro AF, Krausgruber T#, Fortelny N, Zhao F, Penz T, Farlik M, Schuster LC, Kuchler A, Tasnády S, Réti M, Zoltán M, Alpar D#, Bödör C#, Schmidl C#, Bock C (2020). Chromatin mapping and single-cell immune profiling defines the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia. Nature Communications 11, 577.
• Schmidl C, Vladimer GI#, Rendeiro AF#, Schnabl S#, [18 middle authors], Shehata M#, Superti-Furga G#, Jäger U#, Bock C (2019). Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nature Chemical Biology, 15, 232-240.